Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13962314 | 0.85 | — | — | |
| SCHEMBL5858590 | 0.82 | — | — | |
| SCHEMBL29750045 | 0.81 | — | — | |
| SCHEMBL17619773 | 0.81 | CRBN (0.55) | CRBNNEK2BACE1HTR2A | |
| SCHEMBL31566947 | 0.81 | — | — | |
| SCHEMBL30874440 | 0.80 | — | — | |
| SCHEMBL11857442 | 0.78 | CRBN (0.33) | CRBN | |
| SCHEMBL29749828 | 0.77 | CRBN (0.52) | CRBNBACE1 | |
| SCHEMBL11858672 | 0.76 | CRBN (0.32) | CRBN | |
| SCHEMBL29749879 | 0.76 | CRBN (0.50) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455792-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | claimed |
| WO-2003049741-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-19 | — | — | WO | claimed |
| US-8952166-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-1455792-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003049741-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | CRBN 2763/4885NEK2 260/4885BACE1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.